CD8A and neoplasm: A potential mediator limiting the impacts of weight loss on tumor progression after VSG was elevated IL-6, which upregulates the checkpoint ligand, programmed death ligand 1 (PD-L1) on myeloid and non-immune cells, and reduced CD8+T cell content in tumors uniquely in VSG-treated mice.